Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Curfman

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
JAMA Health Forum|October 11, 2022
The 340B Drug Discount Program Preserved After US Supreme Court Review-But Chevron Remains VulnerableGregory Curfman, Justin Cole
Open Heart|April 23, 2021
Icosapent ethyl: scientific and legal controversiesGregory Curfman, Emile Shehada
Healthcare (Amsterdam, Netherlands)|June 26, 2016
Supreme Court scrutinizes all-payer claims databasesCarmel Shachar, Gregory Curfman
JAMA|August 7, 2019
Patient Assistance Programs and Anti-Kickback LawsKatherine Kraschel, Gregory Curfman
JAMA|March 4, 2020
Relentless Prescription Drug Price IncreasesChaarushena Deb, Gregory Curfman
JAMA|April 10, 2023
US Preventive Services Task Force Challenged in Federal CourtGregory Curfman, Kirsten Bibbins-Domingo
JAMA Cardiology|October 23, 2018
Patenting Laws of Nature: Effect on Cardiovascular InnovationMarcia M Boumil, Gregory Curfman
JAMA|March 28, 2024
Reporting on Health and War in Medical JournalsGregory Curfman, Kirsten Bibbins-Domingo
JAMA Internal Medicine|September 14, 2020
The Affordable Care Act Returns to the Supreme Court: Maine Community Health Options v United StatesMarcia M Boumil, Gregory Curfman
JAMA|July 25, 2018
Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product LabelsMarcia M Boumil, Gregory Curfman
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
JAMA Health Forum|October 11, 2022
The 340B Drug Discount Program Preserved After US Supreme Court Review-But Chevron Remains VulnerableGregory Curfman, Justin Cole
Open Heart|April 23, 2021
Icosapent ethyl: scientific and legal controversiesGregory Curfman, Emile Shehada
Healthcare (Amsterdam, Netherlands)|June 26, 2016
Supreme Court scrutinizes all-payer claims databasesCarmel Shachar, Gregory Curfman
JAMA|August 7, 2019
Patient Assistance Programs and Anti-Kickback LawsKatherine Kraschel, Gregory Curfman
JAMA|March 4, 2020
Relentless Prescription Drug Price IncreasesChaarushena Deb, Gregory Curfman
JAMA|April 10, 2023
US Preventive Services Task Force Challenged in Federal CourtGregory Curfman, Kirsten Bibbins-Domingo
JAMA Cardiology|October 23, 2018
Patenting Laws of Nature: Effect on Cardiovascular InnovationMarcia M Boumil, Gregory Curfman
JAMA|March 28, 2024
Reporting on Health and War in Medical JournalsGregory Curfman, Kirsten Bibbins-Domingo
JAMA Internal Medicine|September 14, 2020
The Affordable Care Act Returns to the Supreme Court: Maine Community Health Options v United StatesMarcia M Boumil, Gregory Curfman
JAMA|July 25, 2018
Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product LabelsMarcia M Boumil, Gregory Curfman
Pageof 7